239 related articles for article (PubMed ID: 37395944)
1. Real-world Management of CML: Outcomes and Treatment Patterns.
Held N; Atallah EL
Curr Hematol Malig Rep; 2023 Oct; 18(5):167-175. PubMed ID: 37395944
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Collins JB; Muluneh B; Profitt S
J Oncol Pharm Pract; 2024 Mar; 30(2):385-396. PubMed ID: 38105466
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
5. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
6. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
7. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L
Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Çiftçiler R; Akın MG; Erat Z; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):8-14. PubMed ID: 36344420
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).
Mikhaeel S; Atallah E
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):333-339. PubMed ID: 36934065
[TBL] [Abstract][Full Text] [Related]
12. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
García-Gutiérrez V; Breccia M; Jabbour E; Mauro M; Cortes JE
J Hematol Oncol; 2022 Jul; 15(1):90. PubMed ID: 35818053
[TBL] [Abstract][Full Text] [Related]
13. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
16. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
17. Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Shoukier M; Kubiak M; Cortes J
Curr Oncol Rep; 2021 Jun; 23(8):91. PubMed ID: 34125316
[TBL] [Abstract][Full Text] [Related]
18. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
19. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
20. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Breccia M; Foà R
Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]